Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Acquisitions & Divestments (2022 - 2024)

Immuneering (IMRX) has 3 years of Change in Acquisitions & Divestments data on record, last reported at $5.5 million in Q4 2024.

  • For Q4 2024, Change in Acquisitions & Divestments fell 71.13% year-over-year to $5.5 million; the TTM value through Dec 2024 reached $31.9 million, down 38.95%, while the annual FY2024 figure was $31.9 million, 38.95% down from the prior year.
  • Change in Acquisitions & Divestments reached $5.5 million in Q4 2024 per IMRX's latest filing, up from $5.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $32.3 million in Q2 2022 and bottomed at $5.0 million in Q3 2023.
  • Average Change in Acquisitions & Divestments over 3 years is $16.1 million, with a median of $19.0 million recorded in 2023.
  • Peak YoY movement for Change in Acquisitions & Divestments: crashed 74.03% in 2023, then increased 12.79% in 2024.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $20.6 million in 2022, then decreased by 7.52% to $19.0 million in 2023, then crashed by 71.13% to $5.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $5.5 million in Q4 2024, $5.0 million in Q2 2024, and $21.4 million in Q1 2024.